PIK3CA and neoplasm: Our results suggest that tumours with activation of both pathways may respond poorly to PI3K pathway inhibitors; recent data from preclinical models and human clinical trials also suggest BEZ235 resistance by tumours that pair activation of Ras and PI3K pathways46, 47, 48, 49, 50.